RVLP
RVL Pharmaceuticals plc [RVLP] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
RVLP Stock Summary
In the News
RVLP Financial details
Company Rating
-
Market Cap
3.14M
Income
-68.27M
Revenue
36.92M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
125
Optionable
No
Shortable
Yes
Earnings
08 Nov 2023
P/E
-0.04
Forward P/E
-
PEG
0.01
P/S
0.09
P/B
0.17
P/C
-
P/FCF
-0.07
Quick Ratio
0.31
Current Ratio
0.38
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.7
EPS next Y
-
EPS next Q
-
EPS this Y
-52.85%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-24.85%
Revenue last 5Y
-28.37%
Revenue Q/Q
-6.5%
EPS Q/Q
100%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-80%
ROE
-155%
ROC
-3.38%
Gross Margin
75%
Oper. Margin
-156%
Profit Margin
-185%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.0026-1.66
52W High
-
52W Low
-
RSI
-
Rel Volume
2.62
Avg Volume
24.42M
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
1.086
-
-
Volatility
0.01%, 0.01%
Prev Close
-
Price
-
Change
-
Company Profile
- Volume Average 24.42M
- Market Capitalization 3.14M
- Employee 125
- CEO Mr. Brian A. Markison
- Headquarters Bridgewater,NJ,US
- IPO Date 2018-10-19
-
Website
https://www.rvlpharma.com 
RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. The company is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.
